Key points
- Glutamine is a physiologically important amino acid; however, clinical requirements vary according to the patient’s condition.
- Oral, enteral, and parenteral glutamine are not the same intervention; formulation, dose, and clinical context should be evaluated separately.
- Safety and patient selection are particularly important when considering high-dose or routine glutamine supplementation in critical illness.
- Some positive human data on gut health pertain to specific patient subgroups and should not be generalized to all gastrointestinal complaints.
What is glutamine?
Glutamine is an amino acid that the body can produce and that plays an important role in protein and nitrogen metabolism. It is also used extensively by enterocytes and immune cells. Metabolic requirements may change during severe illness; this has increased the importance of glutamine in clinical nutrition and led to its investigation as a supportive treatment in different patient groups.
Its role in clinical nutrition
Parenteral glutamine may be considered in dipeptide formulations within specific clinical nutrition plans. Oral, enteral, and intravenous nutrition options are selected based on gastrointestinal function, energy and protein requirements, acute disease burden, and organ function. Therefore, glutamine supplementation should be regarded as part of a comprehensive nutrition plan for an appropriate patient rather than as a standalone “IV infusion ingredient.”
Why is special caution needed in critically ill patients?
In the REDOXS randomized trial, which included critically ill patients with multiple organ failure, an early, high-dose glutamine approach did not demonstrate the expected clinical benefit and was associated with findings that raised safety concerns regarding mortality. Current clinical nutrition guidelines also emphasize careful patient selection for parenteral glutamine use, particularly in unstable intensive care patients and in conditions such as kidney or liver failure. Therefore, glutamine supplementation in critically ill patients should be evaluated according to the clinical context rather than as a routine general supportive approach.
Gut health research
Oral glutamine has been studied in selected patients with postinfectious diarrhea-predominant irritable bowel syndrome and increased intestinal permeability, and positive clinical outcomes have been reported. These findings are of interest; however, they should not be directly generalized to all types of irritable bowel syndrome, all intestinal complaints, or intravenous glutamine administration. The priority is an accurate diagnosis, nutritional assessment, and a standard treatment plan.
What is evaluated before administration?
Appetite, weight changes, daily protein and energy intake, gastrointestinal complaints, and any existing nutritional support are reviewed. Kidney and liver function, acute infection or critical illness status, medications used, and other nutritional products are included in the evaluation. The form and route of administration of the product to be used should be consistent with the clinical need.
Safety and practical points
The safety profile of glutamine may vary according to dose, route of administration, and patient group. The “more glutamine is better” approach is not appropriate, particularly in severe organ failure, illness requiring intensive care, or multiple metabolic problems. For parenteral administration, product standards, sterility, admixture compatibility, and the overall nutrition prescription should be evaluated together.
Our approach at our Bodrum clinic
We do not evaluate glutamine solely under the label of gut or immune support. First, the individual’s nutritional status, weight and muscle loss, gastrointestinal complaints, kidney and liver function, and the intended clinical outcome are addressed. Oral supplementation and intravenous use are distinguished from one another; IV administration is considered only when an appropriate product, route of administration, and clinical rationale are present.
Frequently asked questions
Does glutamine support gut health?
It is an important substrate in intestinal cell metabolism, and there are positive research findings with oral glutamine in selected patient groups. Which patients may meaningfully benefit from this should be assessed based on the gastrointestinal diagnosis.
Does the fact that immune cells use glutamine mean that everyone should take supplements?
No; cellular requirements and the clinical benefit of additional supplementation are not the same thing. The decision to provide supplementation should be made in conjunction with the individual’s nutritional status and illness.
Are oral glutamine and IV glutamine the same?
The route of administration, pharmacokinetic properties, formulation, and safety requirements differ. Research findings for one route of administration should not automatically be extrapolated to another.
Related content
References
- Heyland DK, et al. REDOXS trial: glutamine and antioxidants in critically ill patients. N Engl J Med. 2013.
- ESPEN guideline on clinical nutrition in the intensive care unit; current clinical nutrition recommendations.
- Zhou Q, et al. Randomized trial of oral glutamine in the context of postinfectious IBS and intestinal permeability.
- NICE. Nutrition support for adults: oral, enteral and parenteral nutrition.
Written and medically reviewed by: Dr. Kerem Çağlayan
Last medical review: 10 September 2026
Disclaimer: This content is intended for general medical information; it is not a substitute for personalized diagnosis or treatment recommendations.
